Innovation in Ophthalmology KPI – 012 Overview November 15, 2021 Safe Harbor and Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about our future expectations, plans and prospects, including but not limited to statements about our acquisition of Combangio, Inc. (the "Acquisition") and the other transactions contemplated by the Acquisition, and any other statements about future expectations, prospects, es ...

Table of Contents ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State ...

Innovation in Ophthalmology KPI – 012 Overview November 15, 2021 Safe Harbor and Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about our future expectations, plans and prospects, including but not limited to statements about our acquisition of Combangio, Inc. (the "Acquisition") and the other transactions contemplated by the Acquisition, and any other statements about future expectations, prospects, es ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q3 2021 Earnings Conference Call November 15, 2021 8:30 AM ET Company Participants Jill Steier – Executive Director, Investor Relations and Corporate Communications Mark Iwicki – Chairman, President and Chief Executive Officer Kim Brazzell – Chief Medical Officer Todd Bazemore – Chief Operating Officer Mary Reumuth – Chief Financial Officer Conference Call Participants Andreas Argyrides – Wedbush Christopher Neyor – JPMorgan François Brisebois – Oppenheimer Chris How ...

Innovation In Ophthalmology Corporate Overview September 2021 NOT FOR PROMOTIONAL USE Disclaimers and Notices 2 This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding Company's products, EYSUVIS®, for the short term (up to two weeks) relief of the signs and symptoms of dry eye disease, INVELTYS®, the first and only topical twice-daily ocular corticostero ...

Innovation In Ophthalmology Corporate Overview August 2021 NOT FOR PROMOTIONAL USE Disclaimers and Notices This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding Company's products, EYSUVIS®, for the short term (up to two weeks) relief of the signs and symptoms of dry eye disease, INVELTYS®, the first and only topical twice-daily ocular corticosteroid fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or othe ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q2 2021 Earnings Conference Call August 5, 2021 8:00 AM ET Company Participants Niranjan Kameswaran - Senior Vice President of Strategy Mark Iwicki - Chairman, President & Chief Executive Officer Todd Bazemore - Chief Operating Officer Mary Reumuth - Chief Financial Officer Kim Brazzell - Chief Medical Officer Conference Call Participants Chris Neyor - JPMorgan François Brisebois - Oppenheimer Tazeen Ahmad - Bank of America Chris Howerton - Jefferies Yi Chen - H.C. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or oth ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2021 Earnings Conference Call May 5, 2021 8:00 AM ET Company Participants Niranjan Kameswaran - SVP, Strategy Mark Iwicki - Chairman, President & CEO Todd Bazemore - COO Mary Reumuth - CFO & Treasurer Conference Call Participants Andreas Argyrides - Wedbush Securities Christopher Neyor - JPMorgan Chase & Co. François Brisebois - Oppenheimer Tazeen Ahmad - Bank of America Merrill Lynch Yi Chen - H.C. Wainwright & Co. Timothy Chiang - Northland Capital Markets Kelly ...